Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday

Prelude Therapeutics (NASDAQ:PRLD) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Prelude Therapeutics to post earnings of ($0.17) per share and revenue of $4.7770 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:30 AM ET.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The company had revenue of $4.58 million for the quarter, compared to the consensus estimate of $4.58 million.

Prelude Therapeutics Trading Down 1.4%

Prelude Therapeutics stock opened at $4.83 on Tuesday. The firm has a market capitalization of $384.66 million, a P/E ratio of -4.83 and a beta of 0.96. The business has a 50-day moving average of $4.41 and a 200-day moving average of $3.79. Prelude Therapeutics has a 1 year low of $0.75 and a 1 year high of $5.69.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its position in Prelude Therapeutics by 170.7% in the first quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares in the last quarter. Marshall Wace LLP acquired a new position in Prelude Therapeutics during the second quarter worth approximately $34,000. XTX Topco Ltd raised its stake in Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after acquiring an additional 17,873 shares during the period. Shay Capital LLC bought a new position in shares of Prelude Therapeutics in the second quarter valued at about $61,000. Finally, Jane Street Group LLC bought a new position in Prelude Therapeutics in the 2nd quarter valued at about $74,000. 79.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PRLD has been the topic of several analyst reports. D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $9.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Prelude Therapeutics in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Wednesday, July 29th. Zacks Research upgraded Prelude Therapeutics to a “hold” rating in a research report on Tuesday, April 28th. Finally, Wall Street Zen raised Prelude Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.67.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.